<?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName art560.dtd?>
<?SourceDTD.Version 5.6.0?>
<?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?origin publisher?>
<?FILEmeta_NEO733 xml ?>
<?FILEmain xml ?>
<?FILEmain pdf ?>
<?FILEgr1 jpg ?>
<?FILEgr2 jpg ?>
<?FILEgr3 jpg ?>
<?FILEmmc1 docx ?>
<?FILEsi1 svg ?>
<?FILEsi2 svg ?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Neoplasia</journal-id>
    <journal-id journal-id-type="iso-abbrev">Neoplasia</journal-id>
    <journal-title-group>
      <journal-title>Neoplasia (New York, N.Y.)</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1522-8002</issn>
    <issn pub-type="epub">1476-5586</issn>
    <publisher>
      <publisher-name>Neoplasia Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8479477</article-id>
    <article-id pub-id-type="pii">S1476-5586(21)00075-0</article-id>
    <article-id pub-id-type="doi">10.1016/j.neo.2021.08.005</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Original Research</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>RosettaSX: Reliable gene expression signature scoring of cancer models and patients</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="au0001">
        <name>
          <surname>Kreis</surname>
          <given-names>Julian</given-names>
        </name>
        <xref rid="aff0001" ref-type="aff">a</xref>
        <xref rid="aff0002" ref-type="aff">b</xref>
      </contrib>
      <contrib contrib-type="author" id="au0002">
        <name>
          <surname>Nedić</surname>
          <given-names>Boro</given-names>
        </name>
        <xref rid="aff0001" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author" id="au0003">
        <name>
          <surname>Mazur</surname>
          <given-names>Johanna</given-names>
        </name>
        <xref rid="aff0001" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author" id="au0004">
        <name>
          <surname>Urban</surname>
          <given-names>Miriam</given-names>
        </name>
        <xref rid="aff0001" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author" id="au0005">
        <name>
          <surname>Schelhorn</surname>
          <given-names>Sven-Eric</given-names>
        </name>
        <xref rid="aff0001" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author" id="au0006">
        <name>
          <surname>Grombacher</surname>
          <given-names>Thomas</given-names>
        </name>
        <xref rid="aff0001" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author" id="au0007">
        <name>
          <surname>Geist</surname>
          <given-names>Felix</given-names>
        </name>
        <xref rid="aff0003" ref-type="aff">c</xref>
      </contrib>
      <contrib contrib-type="author" id="au0008">
        <name>
          <surname>Brors</surname>
          <given-names>Benedikt</given-names>
        </name>
        <xref rid="aff0004" ref-type="aff">d</xref>
        <xref rid="aff0005" ref-type="aff">e</xref>
      </contrib>
      <contrib contrib-type="author" id="au0009">
        <name>
          <surname>Zühlsdorf</surname>
          <given-names>Michael</given-names>
        </name>
        <xref rid="aff0003" ref-type="aff">c</xref>
      </contrib>
      <contrib contrib-type="author" id="au0010">
        <name>
          <surname>Staub</surname>
          <given-names>Eike</given-names>
        </name>
        <email>eike.staub@merckgroup.com</email>
        <xref rid="aff0001" ref-type="aff">a</xref>
        <xref rid="cor0001" ref-type="corresp">⁎</xref>
      </contrib>
      <aff id="aff0001"><label>a</label>Department of Translational Medicine, Oncology Bioinformatics, Merck KGaA, Darmstadt, Germany</aff>
      <aff id="aff0002"><label>b</label>Faculty of Bioscience, University of Heidelberg, Heidelberg, Germany</aff>
      <aff id="aff0003"><label>c</label>Therapeutic Innovation Platform Oncology &amp; Immuno-Oncology, Merck KGaA, Darmstadt, Germany</aff>
      <aff id="aff0004"><label>d</label>Division of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany</aff>
      <aff id="aff0005"><label>e</label>German Cancer Consortium (DKTK), Core Center, Heidelberg, Germany</aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor0001"><label>⁎</label>Corresponding author. <email>eike.staub@merckgroup.com</email></corresp>
    </author-notes>
    <pub-date pub-type="pmc-release">
      <day>25</day>
      <month>9</month>
      <year>2021</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
    <pub-date pub-type="collection">
      <month>11</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>25</day>
      <month>9</month>
      <year>2021</year>
    </pub-date>
    <volume>23</volume>
    <issue>11</issue>
    <fpage>1069</fpage>
    <lpage>1077</lpage>
    <history>
      <date date-type="received">
        <day>11</day>
        <month>6</month>
        <year>2021</year>
      </date>
      <date date-type="rev-recd">
        <day>28</day>
        <month>8</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>30</day>
        <month>8</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2021 The Authors. Published by Elsevier Inc.</copyright-statement>
      <copyright-year>2021</copyright-year>
      <copyright-holder/>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
      </license>
    </permissions>
    <abstract id="abs0001">
      <p>Gene expression signatures have proven their potential to characterize important cancer phenomena like oncogenic signaling pathway activities, cellular origins of tumors, or immune cell infiltration into tumor tissues. Large collections of expression signatures provide the basis for their application to data sets, but the applicability of each signature in a new experimental context must be reassessed. We apply a methodology that utilizes the previously developed concept of coherent expression of genes in signatures to identify translatable signatures before scoring their activity in single tumors. We present a web interface (www.rosettasx.com) that applies our methodology to expression data from the Cancer Cell Line Encyclopaedia and The Cancer Genome Atlas. Configurable heat maps visualize per-cancer signature scores for 293 hand-curated literature-derived gene sets representing a wide range of cancer-relevant transcriptional modules and phenomena. The platform allows users to complement heatmaps of signature scores with molecular information on SNVs, CNVs, gene expression, gene dependency, and protein abundance or to analyze own signatures. Clustered heatmaps and further plots to drill-down results support users in studying oncological processes in cancer subtypes, thereby providing a rich resource to explore how mechanisms of cancer interact with each other as demonstrated by exemplary analyses of 2 cancer types.</p>
    </abstract>
    <kwd-group id="keys0001">
      <title>Keywords</title>
      <kwd>Gene expression signature</kwd>
      <kwd>Cancer expression profiling</kwd>
      <kwd>Cancer subtypes</kwd>
      <kwd>Multiomics Analyses</kwd>
      <kwd>Analyses</kwd>
      <kwd>Web service</kwd>
    </kwd-group>
  </article-meta>
</front>
<body>
  <p id="para9001">
    <def-list>
      <title>Abbreviations</title>
      <def-item>
        <term id="dt0001">ABC</term>
        <def>
          <p id="para0001">Activated B-cell like</p>
        </def>
      </def-item>
      <def-item>
        <term id="dt0002">CCLE</term>
        <def>
          <p id="para0002">Cancer Cell Line Encyclopaedia</p>
        </def>
      </def-item>
      <def-item>
        <term id="dt0003">CPM</term>
        <def>
          <p id="para0003">Counts per million</p>
        </def>
      </def-item>
      <def-item>
        <term id="dt0004">CS</term>
        <def>
          <p id="para0004">Coherence score</p>
        </def>
      </def-item>
      <def-item>
        <term id="dt0005">DI</term>
        <def>
          <p id="para0005">Deregulation Index</p>
        </def>
      </def-item>
      <def-item>
        <term id="dt0006">EMT</term>
        <def>
          <p id="para0006">Epithelial-mesenchymal transition</p>
        </def>
      </def-item>
      <def-item>
        <term id="dt0007">ER</term>
        <def>
          <p id="para0007">Estrogen receptor</p>
        </def>
      </def-item>
      <def-item>
        <term id="dt0008">GCB</term>
        <def>
          <p id="para0008">Germinal centre B-cell-like</p>
        </def>
      </def-item>
      <def-item>
        <term id="dt0009">PR</term>
        <def>
          <p id="para0009">Progestosteron receptor</p>
        </def>
      </def-item>
      <def-item>
        <term id="dt0010">TCGA</term>
        <def>
          <p id="para0010">The Cancer Genome Atlas</p>
        </def>
      </def-item>
      <def-item>
        <term id="dt0011">TMM</term>
        <def>
          <p id="para0011">Trimmed mean of M-values</p>
        </def>
      </def-item>
      <def-item>
        <term id="dt0012">TPM</term>
        <def>
          <p id="para0012">Transcripts per million</p>
        </def>
      </def-item>
    </def-list>
  </p>
  <sec id="sec0001">
    <title>Introduction</title>
    <p id="para0013">The tumor-specific gene expression phenotype is the product of a coordinated interplay of cellular and pathway-related transcription modules <xref rid="bib0001" ref-type="bibr">[1]</xref>. These modules of coexpressed genes, also called expression signatures, describe many functional aspects of a tumor, like cell-type composition <xref rid="bib0002" ref-type="bibr">[2]</xref>, signaling pathway activities <xref rid="bib0003" ref-type="bibr">[3]</xref>, activities of fundamental cellular processes like proliferation or interferon response <xref rid="bib0004" ref-type="bibr">[4]</xref>, or can even inform on the cell-of-origin of a tumor. Cancer subtype signatures have been identified, for example, for tumors of the colon <xref rid="bib0005" ref-type="bibr">[5]</xref>, breast <xref rid="bib0006" ref-type="bibr">[6</xref>,<xref rid="bib0007" ref-type="bibr">7]</xref>, or diffuse large B-cell carcinoma <xref rid="bib0008" ref-type="bibr">[8]</xref>. Further, during tumorigenesis, the accumulation of somatic alterations in tumors often results in specific expression phenotypes, enabling cancers to develop cancer hallmark properties <xref rid="bib0009" ref-type="bibr">[9]</xref>. Therefore, the investigation of expression signatures today plays an essential role in the elucidation of tumor biology.</p>
    <p id="para0014">Expression signatures have also become widely used during drug development, for support of clinical cancer diagnosis <xref rid="bib0010" ref-type="bibr">[10]</xref>. The exploration of signatures has become a standard component for cancer subtyping in major multiomics patient cohort studies and often provides a framework for the interpretation of somatic mutations <xref rid="bib0011" ref-type="bibr">[11]</xref>. Hundreds of signatures have been proposed for concrete clinical use in the last 2 decades, either to inform on patient prognosis <xref rid="bib0012" ref-type="bibr">[12]</xref> or to predict therapeutic efficacy based on cancer gene expression at baseline of therapy <xref rid="bib0013" ref-type="bibr">[13]</xref>. Furthermore, the connectivity map approach, which, for the first time, proposed the reversal of disease signatures by therapeutic drugs, has developed into a widely used method in drug discovery <xref rid="bib0014" ref-type="bibr">[14]</xref>. It was extended later to include gene knock-down/out-induced perturbations. Thereby, it enables to generate a broader understanding of the mode of actions of drugs and gene perturbations in relation to a user-defined gene expression signature.</p>
    <p id="para0015">Given the importance of expression signatures for understanding tumor biology and drug response, it is essential to reliably identify sets of high-quality expression signatures that can be used to score the activity of functional expression modules in a new expression data set, independent of whether it is an interventional experimental study, a study across model organisms or a patient cohort study. To this end, a careful selection of published high-quality gene expression signatures is crucial. It should cover a broad range of underlying phenomena to characterize the activities of all cancer hallmark mechanisms comprehensively <xref rid="bib0009" ref-type="bibr">[9]</xref>. Throughout the last decades, different collections of gene modules were developed. The MSigDB collection is one of the largest resources for published expression signatures. Despite its comprehensive coverage of literature-published expression signatures, it is not necessarily best suited to efficiently characterize new cancer expression data for 2 reasons. First, the collection comprises many noisy signatures that lack validation in independent datasets or are strongly influenced by confounding mechanisms. For example, many signatures are "polluted" by high fractions of cell-cycle-controlled genes, which render their net scores like typical proliferation signatures <xref rid="bib0015" ref-type="bibr">[15]</xref>, a problem especially in oncology with a range of mechanisms that affect cell proliferation. As a consequence of this problem, most random gene sets in breast cancer lead to prognostic signatures because proliferation as a mechanism is prognostically relevant <xref rid="bib0016" ref-type="bibr">[16]</xref>. Further, redundancy and bias create difficulties for efficient control of type I errors in statistical testing, thereby reducing the power of analyses.</p>
    <p id="para0016">Another collection of signatures to characterize cancer expression data is the cancer hallmark signatures published by the MSigDB team that cover 50 carefully selected gene sets <xref rid="bib0037" ref-type="bibr">[36]</xref>. Although they probably cover the majority of cancer-relevant expression phenotypes, the collection does not comprise many well-known and frequently used signatures for the diagnosis of distinct cancer subtypes. So, when using this limited collection only, the result has shortcomings when trying to bridge own results with findings in the literature. Also, it is advantageous for a collection to have at least a few signatures for a single phenomenon, i.e., to cover phenomena with small, controlled redundancy (as long as gene lists do not overlap significantly). A limited redundancy can add credibility to results observed for a specific phenomenon because phenomena-specific signatures originally postulated by independent research groups can more convincingly support a particular result. In conclusion, there is room for a curated signature collection that tries to comprehensively capture the most prevalent signatures used in different cancer communities while avoiding too much redundancy and bias that would blow up the multiple testing problem.</p>
    <p id="para0017">A gene expression module might not always be relevant in a new data set not used for its discovery. Rationales for the assessment of relevance or translatability of a signature into a new data context have been published before <xref rid="bib0018" ref-type="bibr">[17</xref>,<xref rid="bib0019" ref-type="bibr">18]</xref>. If a cancer expression module is coordinately up-regulated across samples of a new data set, then this is a sign of biological importance. A footprint of pairwise correlations between module genes across all samples of a study justifies the relevance of a gene expression module in that specific data set. On the other side, biological irrelevance, technical noise or different patient characteristics in the investigated cohort might lead to the absence of such correlations. Therefore, the translatability of a signature on a new dataset can be assessed by analysis of the correlation structure of the signatures' genes in the new data set. If genes of a signature do correlate with each other, there are some samples in the data that share high expression of the genes in the module indicating a common positive transcriptional regulation of the module that can be the result of diverse biological phenomena such as a particular differentiation state of cells or an upstream pathway activity. One metric for translatability assumes pairwise correlated gene expression to signify translatability of a biological signal. This rationale, to our knowledge, has first been proposed by Rahnenführer <italic>et al.</italic>
<xref rid="bib0020" ref-type="bibr">[19]</xref>, but, since then, has been proposed in several studies <xref rid="bib0021" ref-type="bibr">[20</xref>,<xref rid="bib0022" ref-type="bibr">21]</xref>. Astonishingly, although the importance of coexpression of signature genes has been recognized, this rationale has, until now, hardly been used in systematic approaches to remove noisy signatures and distil conclusive results during the analyses of large-scale signature collections on novel expression data sets.</p>
    <p id="para0018">In this work, we aim to provide (1) a well-balanced collection of high-fidelity signatures from the literature, (2) an algorithm or workflow to evaluate the applicability of a signature in a new data set and score it on single tumors, and (3) a web-based analytical system for analysis of activities of such signatures. We introduce RosettaSX, a platform that helps users unravel complex processes with robust gene expression signatures. It not only provides robust expression portraits based on underlying expression data, but it also enables users to explore the associations between signature activities and molecular aberrations like somatic mutations and gene copy number changes <xref rid="bib0050" ref-type="bibr">[49]</xref>, <xref rid="bib0051" ref-type="bibr">[50]</xref> or even profiles from gene dependency screens <xref rid="bib0047" ref-type="bibr">[46]</xref>, <xref rid="bib0048" ref-type="bibr">[47]</xref>, <xref rid="bib0049" ref-type="bibr">[48]</xref>.</p>
  </sec>
  <sec id="sec0002">
    <title>Materials and methods</title>
    <p id="para0019">Before signature assessment, for each cancer indication, we normalize each expression dataset separately using the trimmed mean of M-values (TMM) normalization <xref rid="bib0023" ref-type="bibr">[22]</xref>. We remove genes with low expression based on a criterion of fewer than ten reads in 70% of the samples or less than 15 reads in the complete dataset before normalization.</p>
    <p id="para0020">For the definition of a per-sample signature score (i.e., signature activity) we use the mean of the gene-wise expression Z-scores; a score previously referred to as the deregulation index (DI) <xref rid="bib0024" ref-type="bibr">[23]</xref>. In detail, we use the average of TMM normalized and z-scaled TPM (accounting for within-sample comparisons) expression values for a set of genes of a signature as a signature score of a single sample.</p>
    <p id="para0021">When applying and interpreting signatures - that have most often been created in other experimental contexts and published in the literature - on a new expression data set, it is beneficial to validate their translatability to these new data first: here to validate the translatability of the RosettaSX signature collection to the TCGA <xref rid="bib0051" ref-type="bibr">[50]</xref> and CCLE <xref rid="bib0050" ref-type="bibr">[49]</xref> expression data. For interpretation of signatures scores we intend to focus only on signatures with strong signs of translatability, leaving aside signatures with low signs of translatability that could rather add noise to an analysis of the whole collection and cause mis- or overinterpretation.</p>
    <p id="para0022">For the assessment of the translatability of a signature to a new data set, we use the coherence score (CS), which is calculated for each signature on each data set as previously published <xref rid="bib0022" ref-type="bibr">[21]</xref>. We refer to the Supplementary Material for a detailed description of the CS. Although the CS has been developed by us; we note that usage of the concept of coexpression to score the relevance of signatures has been developed independently by other groups <xref rid="bib0020" ref-type="bibr">[19]</xref>, <xref rid="bib0021" ref-type="bibr">[20]</xref>, <xref rid="bib0022" ref-type="bibr">[21]</xref>. Briefly, for a signature with <inline-formula><mml:math id="M1" altimg="si1.svg"><mml:mi>n</mml:mi></mml:math></inline-formula> genes, we calculate the average of all pairwise Pearson correlation coefficients of the TMM normalized Z-scaled counts per million (CPM) values (accounting for between-sample comparisons). A score close to the limits <inline-formula><mml:math id="M2" altimg="si2.svg"><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mspace width="0.28em"/><mml:mtext>and</mml:mtext><mml:mspace width="0.28em"/></mml:mrow><mml:mo linebreak="badbreak">−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>n</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> indicates a coherent up- or downregulation of all genes within a signature in a dataset under study.</p>
    <p id="para0023">We conducted extensive assessments of the significance of CSs based on permuted expression data and randomly sampled signatures, and also investigated the dependence of significance on the number of genes in the signature (see Supplementary Figure 1-4). We find that CSs greater than 0.20 (our default RosettaSX threshold) indicate high confidence in the translatability of signatures as indicated by empirical p-values and by a very strong correlation of signature scoring methods for such high CSs, even if signatures are small in the number of genes. For larger signatures with more than 20 genes even CSs between 0.12 and 0.20 already suggest that signatures can be regarded as informative in a data set (see Supplementary Figure 1). We also found that ours and various other signature scoring methods are in good agreement with each other if – and only if - the CS of the signature is high (see Supplementary Figure 4 in which correlation of various scoring methods is excellent for a threshold of CS&gt;0.2) supporting our conclusion that in these situations signatures can be called translatable to a new data set. Whereas application of our signature collection on TCGA BRCA data leads to dozens of signatures with CS&gt;0.2, not a single signature exceeds the CS&gt;0.2 threshold in a collection of equally sized randomly sampled signatures (Supplementary Figure 2).</p>
    <p id="para0024">All this confirms (1) that our choice of scoring method is reasonable and (2) that CS-based filtering of signatures leads to results that are robust to small changes in methodology. Thus, the combination of signature prefiltering for translatability using the CS with per-sample signature scoring by the DI is a reliable approach for analysis and interpretation of whole signature collections in tumor expression data.</p>
  </sec>
  <sec id="sec0003">
    <title>Results</title>
    <p id="para0025">In the following, we describe how our system enables users to perform in-depth analyses of gene expression signatures based on expression data of cancer models or patients. Then, we demonstrate the potential of RosettaSX to confirm known and discover new expression subtype relations: we demonstrate this by 2 analyses of our gene expression signature collection in breast cancer, and in diffuse large B cell lymphoma.</p>
    <sec id="sec0004">
      <title>RosettaSX web application enables comprehensive expression signature analyses</title>
      <p id="para0026">A typical workflow for the usage of the platform is shown in <xref rid="fig0001" ref-type="fig">Figure 1</xref>. First, the user selects the data source (TCGA patients or CCLE cell lines) and the cancer type of interest. Then, the user needs to specify how to narrow down the available signatures, each describing a biological expression phenotype. Most available signatures in our collection have been discovered on other data than from TCGA and CCLE. Therefore, an evaluation of the robustness or translatability of each signature in the selected data is highly recommended. We offer to test for the coherence of a signature on a new dataset. We consider a signature to be translatable to the respective dataset if a certain threshold of the coherence score is exceeded (see methods).<fig id="fig0001"><label>Fig. 1</label><caption><p>RosettaSX analysis workflow for expression signature analysis. Our workflow is an iterative procedure that uses the expression phenotypes of signatures to characterize an indication of interest. The user can narrow down the available signatures based on gene set size, availability of genes in the new data, or intrasignature expression coherence. Additionally, the annotation of a wide range of molecular and phenotypic data allows to characterize RosettaSX analysis findings. Depending on the research question, users can choose between a clustered and profile guided heatmap representation. Users can drill-down associations between pairs of annotation parameters or signature scores using box plots and scatter plots.</p></caption><alt-text id="alt0001">Fig 1</alt-text><graphic xlink:href="gr1"/></fig></p>
      <p id="para0027">After signature filtering, the user can interactively add molecular data (e.g., expression, copy number, and mutation data) for a gene of interest or sample phenotype annotations (i.e., tumor subtype) or compute the signature score for a gene set of interest.</p>
      <p id="para0028">The web server's key analysis output is a heat map that displays the selected gene expression signature profiles and optionally the selected annotations. Two types of views allow the user to discover different research questions, the profile-guided and clustered view. The clustered view (the default) allows to group together all closely related signatures, which could highlight expression subtypes in the selected dataset. For the profile-guided view, we correlate a continuous annotation with signature scores and order the signatures descending by their correlation coefficient. This view enables discoveries of associations between a selected annotation and the phenotypes that are described by the signatures. Through the interactive web server, the user can then optimize the presentation of his results with further annotations or can adjust the filter criteria.</p>
    </sec>
    <sec id="sec0005">
      <title>Intrinsic breast cancer expression subtypes rediscovered in the TCGA breast cancer cohort</title>
      <p id="para0029">Today, the most essential and treatment-relevant classification of breast cancer depends on the expression states of the estrogen receptor (ER), the progesterone receptor (PR), the epidermal growth factor receptor 2 (HER2) <xref rid="bib0025" ref-type="bibr">[24]</xref>, and the assessment of cell proliferation activity like Ki67 <xref rid="bib0026" ref-type="bibr">[25]</xref>. Besides these classical markers, commercial gene expression signature tests are applied in the clinical setting for prognosis of breast cancer patients. The most well-known assay is based on work by Perou <italic>et al.</italic>, who described 5 intrinsic subtypes of breast cancer (PAM50) that reconcile the states of these receptors with cell-of-origin expression patterns and describe specific genomic and clinical characteristics: luminal A and B, basal-like, normal-like, and HER2-enriched <xref rid="bib0006" ref-type="bibr">[6</xref>,<xref rid="bib0027" ref-type="bibr">26]</xref>. Using RosettaSX, we reassess the PAM50 signatures in breast cancer along with classical marker annotations and many other gene expression signatures that were published to be informative to explain breast cancer biology. <xref rid="fig0002" ref-type="fig">Figure 2</xref> shows the output of RosettaSX. The status of ER, PR, and HER2 receptors <xref rid="bib0028" ref-type="bibr">[27</xref>,<xref rid="bib0029" ref-type="bibr">28]</xref>, the PAM50 subtypes <xref rid="bib0029" ref-type="bibr">[28]</xref> as provided by the TCGA consortium, supplemented by gene expression, SNV, and CNV data of some breast-cancer relevant genes are displayed at the top of the heatmap.<fig id="fig0002"><label>Fig. 2</label><caption><p>RosettaSX analysis of intrinsic subtypes in the TCGA breast cancer cohort. The heatmap displays expression signature scores (threshold CS ≥ 0.2, 80–100% genes available and expressed, signature size: 3–300) that characterize various robust expression programs and their biological contexts (left text and color annotations) in the PAM50 subtypes. The column (sample) annotations above the heat map display clinical patient markers <xref rid="bib0040" ref-type="bibr">[39</xref>,<xref rid="bib0041" ref-type="bibr">40]</xref> and molecular configurations of single genes (to be selected). The sample annotation comprises: estrogen receptor status (ER), progesterone receptor status (PR), HER2 receptor status (HER2) with positive status in green, negative status in orange, ERBB2 gene amplification (light green) in the HER2 subtype (red), elevated ESR1 expression (orange) in the luminal subtypes (light and dark orange), TP53 mutations in the basal (yellow) subtype, high expression of the MKI67 proliferation marker in basal, luminal B and HER subtype and low expression in the normal-like subtype) align with known properties of the intrinsic subtypes. Bold row labels emphasize signatures that are postulated to describe the different intrinsic subtypes.</p></caption><alt-text id="alt0002">Fig. 2</alt-text><graphic xlink:href="gr2"/></fig><fig id="fig0003"><label>Fig. 3</label><caption><p>RosettaSX results for the characterisation of the TCGA Diffuse Large B Cell Lymphoma cohort. We show expression signature scores per tumor for signatures selected by following criteria: CS ≥ 0.13; 90-100% genes available; signature size: 3-300 The annotation above the heatmap shows TCGA annotated GCB and ABC (light blue) subtypes with unclassified tumors in grey. In addition, the international prognostic index and the expression intensities of BCL2, BCL6 and MYC are given below. The uppermost and bottommost branches of the dendrogram on the left side represent clusters with ABC and GCB related signatures, respectively.</p></caption><alt-text id="alt0002a">Figure 3</alt-text><graphic xlink:href="gr3"/></fig></p>
      <p id="para0030">The phenotypic annotations not only align with known traits of the different subtypes but also validate our gene expression pre-processing approach. The ESR1 expression agrees with the annotated ER status (two-sided Wilcoxon-test, <italic>P</italic>-value: &lt; 2.2e-16, <xref rid="fig0002" ref-type="fig">Figure 2</xref> and Supplementary Figure 5.A). The status of ER and PR are known to be generally positive in the luminal PAM50 subtypes <xref rid="bib0027" ref-type="bibr">[26]</xref>, which is congruent with our findings. Our signature collection comprises 2 signatures of Calza <italic>et al.</italic>
<xref rid="bib0006" ref-type="bibr">[6]</xref> that were postulated to characterize luminal A and luminal B subtypes, respectively. Our results indicate that in the TCGA BRCA dataset the luminal A signature is sufficient to identify the luminal or ER+ subtype with elevated levels in both TCGA-annotated luminal subtypes (Supplementary Figure 5.B, fourth plot). As described by several studies, the luminal B subtype is strongly associated with proliferation <xref rid="bib0030" ref-type="bibr">[29</xref>,<xref rid="bib0031" ref-type="bibr">30]</xref>. In our analysis, this is reflected by coclustering of luminal B and proliferation signatures, both of which are elevated in the TCGA-annotated luminal B subtype. The HER2 subtype classification can be validated on both the genomic and transcriptomic level. As initially postulated by Perou <italic>et al.</italic>
<xref rid="bib0027" ref-type="bibr">[26]</xref>, we also observe a significant difference of ERBB2 gene copy number (DNA level) between subtypes (chi-square, <italic>P</italic>-value: 8.2e-5), with the highest frequency in the HER2 PAM50 expression subtype (<xref rid="fig0002" ref-type="fig">Figure 2</xref> and Supplementary Figure 5.A, second plot). Our RosettaSX heatmap comprises multiple nonidentical signatures for the ERBB2 subtype <xref rid="bib0006" ref-type="bibr">[6</xref>,<xref rid="bib0007" ref-type="bibr">7]</xref> (Supplementary Figure 5.B, third plot) which match the PAM50 HER2 annotation well but also are associated with ERBB2 gene copy number.</p>
      <p id="para0031">The basal subtype of breast cancer is defined by a cell-of-origin signature expressed by epithelial cells in the basal or outer layer of the mammary gland <xref rid="bib0027" ref-type="bibr">[26]</xref>. This subtype is a major clinical challenge because these tumors are aggressive, prevalent in young woman, and often relapse rapidly <xref rid="bib0032" ref-type="bibr">[31]</xref>. The basal subtype is known to be nearly congruent with the ER-negative subtype; often also the progesterone and HER2 receptors are negative in these cancers. Indeed, basal cancers constitute the largest fraction of the so-called triple-negative breast cancer (TNBC) group that is difficult to treat and has a poor prognosis <xref rid="bib0032" ref-type="bibr">[31</xref>,<xref rid="bib0033" ref-type="bibr">32]</xref>. In our analysis, the mRNA expression patterns of the ESR1 and PR genes, the basal subtype signature by Calza <italic>et al.</italic>, the clinical annotation of ER and PR status, and the TCGA annotation of the PAM50 basal subtype nicely recapitulate all these relationships (<xref rid="fig0002" ref-type="fig">Figure 2</xref>).</p>
      <p id="para0032">Basal breast cancers also exhibit the highest frequency of TP53 mutations according to our analysis. Further, the occurrence of TP53 mutations across all breast cancers also correlates with strong signals of the signatures of Miller <italic>et al.</italic> and Troester <italic>et al.</italic>
<xref rid="bib0034" ref-type="bibr">[33</xref>,<xref rid="bib0035" ref-type="bibr">34]</xref>. Their signatures are part of a larger cluster comprising many proliferation signatures. These relationships suggest a link between loss-of-function of TP53 <xref rid="bib0034" ref-type="bibr">[33</xref>,<xref rid="bib0035" ref-type="bibr">34]</xref>, proliferative aggressiveness of the tumors <xref rid="bib0036" ref-type="bibr">[35</xref>,<xref rid="bib0037" ref-type="bibr">36]</xref>, and enrichment of these molecular configurations in the basal subtype <xref rid="bib0006" ref-type="bibr">[6</xref>,<xref rid="bib0007" ref-type="bibr">7]</xref>. Lehmann <italic>et al.</italic> have investigated the subtype structure of TNBCs and described 6 TNBC subtypes <xref rid="bib0038" ref-type="bibr">[37]</xref>. Two of their signatures can even be robustly translated into the TCGA breast cancer data set: the immunomodulatory (IMM) subtype signature matches the profiles of many other inflammatory signatures and marks a high fraction of basal breast cancers as immune-hot. The basal-like 2 (BL2) signature is most strongly up-regulated in the basal subtype in agreement with the finding of Lehmann <italic>et al.</italic> They also described an association of the BL2 subtype with RTK pathway activation (EGFR, NGF, MET, IGF1R) and glycolysis. This is compatible with our findings of a weaker, but substantial BL2 subtype signature signal in the normal PAM50 subtype, indicative of a differentiated epithelial phenotype.</p>
      <p id="para0033">Proliferation activity of breast cancers is strongly linked to poor prognosis <xref rid="bib0016" ref-type="bibr">[16]</xref>. Ki67 protein expression is an important standard marker used to determine the fraction of cells undergoing mitosis and is part of routine diagnostics procedures for breast cancer. Our RosettaSX analysis reveals a large cluster of signatures that are linked to proliferation, comprising, among others signatures by Farmer et. al and Budinska et al. (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>).These proliferation signatures show a strong correlation to the mRNA expression signal of iMKI67 (Supplementary Figure 6). High cell cycle activity can predominantly be observed in the basal, HER2, and luminal B subtypes (Supplementary Figure 6, first plot). This is consistent with earlier findings of higher proliferation rates in basal, HER2, and luminal B subtypes <xref rid="bib0006" ref-type="bibr">[6</xref>,<xref rid="bib0039" ref-type="bibr">38]</xref>. It is noteworthy that the luminal B signature of Calza <italic>et al.</italic> clusters with proliferation signatures and is not primarily associated with the PAM50 luminal B subtype, whereas the luminal A signature is indicative of all luminal cancers (nearly congruent with the ER+ subtype). So, whereas the luminal cell-of-origin instead seems to be captured by the luminal A signature, the luminal B signature captures the phenomenon of mitotic activity (Supplementary Figure 5.AIII), thereby providing an analogous alternative to traditional ER-positivity and the fraction of tumor cells undergoing mitoses (Supplementary Figure 5.B, first plot). This is consistent with earlier findings of higher proliferation rates in basal, HER2, and luminal B subtypes <xref rid="bib0006" ref-type="bibr">[6</xref>,<xref rid="bib0039" ref-type="bibr">38]</xref>. It is noteworthy that the luminal B signature of Calza <italic>et al.</italic> clusters with proliferation signatures and is not primarily associated with the PAM50 luminal B subtype, whereas the luminal A signature is indicative of all luminal cancers (nearly congruent with the ER+ subtype). So, whereas the luminal cell-of-origin instead seems to be captured by the luminal A signature, the luminal B signature captures the phenomenon of mitotic activity (Supplementary Figure 5.AIII), thereby providing an analogous alternative to traditional ER-positivity and the fraction of tumor cells undergoing mitoses.</p>
      <p id="para0034">Many further signatures yield sufficient coherence scores, thus suggest that the interpretation of their scores is warranted. For example, we observe a high inflammation signature activity in subsets of samples within each PAM50 subtype. This has been described before for other cohorts by one of us <xref rid="bib0040" ref-type="bibr">[39]</xref> and is thought to indicate immune cell infiltration. As immune cell infiltration is a pre-requisite for anti-tumor immune response, such signatures have been proposed to classify tumors into immunologically “hot” or “cold” <xref rid="bib0041" ref-type="bibr">[40]</xref>. Furthermore, we observe the imperfect association of multiple immune cell-type-specific signatures (T-cell, B-cell, and NK-cells) with general immune activation signatures. Fine-grained differences in these patterns, pointing to the absence or presence of a specific cell type, could help to identify the immune status of a tumor more precisely.</p>
      <p id="para0035">A cluster of signatures at the bottom of our heatmap is related to the differentiation status of breast cancers. Stemness or mesenchymality of cancer, for example, after epithelial-mesenchymal transition (EMT), is often associated with poor prognosis, tendency to metastasise, and with resistance to chemotherapy [<xref rid="bib0004" ref-type="bibr">[4</xref>,<xref rid="bib0042" ref-type="bibr">41]</xref>]. While studies on cell-lines suggested that EMT is active in basal and claudin-low breast cancers <xref rid="bib0004" ref-type="bibr">[4]</xref>, our analysis partly aligns with recent studies on primary tumors that showed higher proportions of EMT high samples in nonbasal subtypes <xref rid="bib0043" ref-type="bibr">[42]</xref> (Supplementary Figure 5.B, second plot). In alignment with the work of Savci–Heijink <italic>et al.</italic>, EMT signatures in this TCGA cohort have higher scores in luminal A, B, and HER2 subtypes than in the basal subtype.</p>
      <p id="para0036">The interactions of tumor cells, tumor associated stromal cells (TASCs) and extracellular matrix (ECM) are crucial for tumor development and progression. In luminal breast cancer, the binding of HER3 (ERBB3) and neuregulin 1 (NRG1) results in PI3K/AKT, MAPK and JAK/STAT signaling which is associated with tumor progression <xref rid="bib0044" ref-type="bibr">[43]</xref>. Berdiel–Acer <italic>et al.</italic> showed that in luminal breast cancers, cancer associated fibroblasts (CAFs) are key producers of NRG1 promoting a paracrine activation of HER3 receptors. In our analysis, there are increased stromal and ECM signature scores in a subset of luminal cancers. HER3 expression is also elevated in luminal cancers and the profile of NRG1 expression strongly correlates with stromal/fibroblast signatures (Supplementary Figure 7). Together these profiles indicate a strong stroma-tumor interaction in a subset of luminal cells supporting NRG1 as a possible biomarker for anti-HER3 therapies.</p>
    </sec>
    <sec id="sec0006">
      <title>Major DLBCL subtypes recapitulated by RosettaSX analysis of DLBCL TCGA cohort</title>
      <p id="para0037">Diffuse large B-cell lymphoma (DLBCL) is a subtype of non-Hodgkin's lymphoma, which is classified by the world health organization into 13 variants with specific morphologic or immune phenotypic features or cases that are not otherwise specified <xref rid="bib0045" ref-type="bibr">[44]</xref>. A well-established gene expression profiling approach for DLBCL is based on expression signatures that are linked to the differentiation status of the tumors cell of origin. While germinal center B-cell-like (GCB) tumors originate from an earlier stage of B cell differentiation, the activated B-cell-like (ABC) tumors derive from a later, more differentiated stage.</p>
      <p id="para0038">Here, we analyze the DLBCL cohort of TCGA. We demonstrate how available ABC and GCB expression signatures perform to classify DLBCL, and how ABC and GCB subtypes are related to activities of other pathways and cellular programs (<xref rid="fig0003" ref-type="fig">Fig. 3</xref>). To this end, we use TCGA-provided GCB and ABC annotations as a reference <xref rid="bib52" ref-type="bibr">[51]</xref>. The heatmap only shows signatures of coherently expressed signatures (CS ≥ 0.13). Our signatures for ABC and GCB subtypes in the heatmap match the TCGA reference annotation very well and even inform on the cancers that remained unclassified by TCGA. The heatmap highlights the molecular diversity of DLBCL by the multitude of signatures for other processes that are relevant during lymphomagenesis <xref rid="bib0008" ref-type="bibr">[8]</xref>. The heatmap highlights strongly different proliferation activities in DLBCL samples that are mostly congruent with the ABC-vs-GCB activation. Strongly proliferating cancers occur at higher frequency in ABC samples as supported by many proliferation signatures, some of them also being informative in breast and colon cancer. In addition, we observe the activation of NF-κB or general immune activation signatures in ABC cancers. Indeed, this is the hallmark feature of activated B cells in which NF-κB pathway activation drives B cells into proliferation and enables them to evade apoptosis <xref rid="bib0046" ref-type="bibr">[45]</xref>. So, the concomitant activation of proliferation and NF-κB signatures in the majority of ABC classified tumors is in agreement with expectations. Also, in those cancers that are tagged by TCGA as unclassified, we can observe activation of proliferation signatures in ABC signature-high cancers, suggesting that TCGA has conservatively assigned subtypes and we can safely extend the annotation for several patients by our analysis of multiple signatures. However, we also see that the association of the ABC phenotype is not perfectly congruent with NF-κB activation and proliferation. The existence of proliferation-high-ABC and proliferation-low-GCB cancers could be an interesting starting point for further studies into the molecular origins of this behavior and the clinical consequences for prognosis and optimal treatment selection. Further, we note that there are strong expression modules that are not at all congruent with ABC and GCB subtypes. Multiple type-I IFN response signatures have very high coherence scores, form a tight cluster, with their profiles being uncorrelated to ABC or GCB signature profiles. This suggests that IFN response activity could be an alternative phenomenon that could be relevant for diagnosis and treatment of DLBCL.</p>
    </sec>
  </sec>
  <sec id="sec0007">
    <title>Discussion and conclusions</title>
    <p id="para0039">We introduced a new workflow for gene expression signature assessment in cancer and a web server that provides easy access to the analysis of 293 carefully selected signatures in 2 well-known large-scale cancer expression datasets. Together, these data cover more than 30 cancer types with more than 11,000 cancer samples. Our platform supports the user in the identification of robust signatures for subtyping of cancer models or patient cohorts with flexible analysis options, high-quality heatmap visualizations and capabilities to drill-down RosettaSX analysis results. To our knowledge, a comparable system has not been made available yet: it fills a gap in the landscape of data analysis tools for the cancer community.</p>
    <p id="para0040">Using RosettaSX, we were able to recapitulate cell-of-origin subtypes and major molecular pathways in 2 cancer indications. In breast cancer, we could show that the signature collection available on RosettaSX is capable of distinguishing luminal, basal and HER2 PAM50 subtypes, with luminal A signature scores matching the luminal basis annotation and the luminal B signature being tightly linked to proliferation as previously published. We were capable to demonstrate that other robust signatures are valid indicators of breast cancer: immune activation, proliferation, TP53 mutation signatures among others match only partially to PAM50 subtypes: multiple signatures always supported their profiles for a phenomenon. Similarly, for DLBCL, we were able to recapitulate the known major expression-based subtyping schemes, the ABC-vs-GCB classification. Still, we could also show that other robust signatures, e.g., related to interferon response, or proliferation, play important roles and are not congruent with subtyping schemes. We argue that our methodology is well suited to study these landscapes of nonmutually exclusive subtyping schemes.</p>
    <p id="para0041">One strength of our approach is our curated collection of signatures. It covers a wide range of biological phenomena and well-accepted subtyping signatures that are specifically relevant for distinct cancer types. Over the past, the provided signatures proved their integrity in a wide range of applications (unpublished work). We argue that rigorous filtering by signature coherence (with significant empirical p-values) combined with a controlled redundancy of non-overlapping signatures is a distinctive and favorable characteristic of our approach. It eliminates signatures with spurious gene-by-gene correlation before performing downstream analyses (here hierarchically clustered heatmaps of signatures). Examples illustrated that using our method we very often identify multiple coherent signatures for major known subtypes (e.g., for PAM50 and ABC/GCB subtypes and proliferation in DLBCL).</p>
    <p id="para0042">Our main criterion for filtering signatures for translatability and describing their activity in a new dataset is the coherence score. We have tested similar metrics <xref rid="bib0018" ref-type="bibr">[17</xref>,<xref rid="bib0019" ref-type="bibr">18]</xref> earlier (unpublished results) and found it to yield similar results to the coherence score. Furthermore, the recapitulated major literature findings described in the results section, proved, that our proposed scores represent signature activity and pinpoint relevant signatures well. The proposed thresholds for coherence scores yield significant empirical p-values for signatures of size greater than ten genes (and even below). Our analyses on the significance of CS based on randomly sampled signatures (Supplementary Figures 1 and 2) or shuffled expression data (Supplementary Figure 3), the agreement of signature scoring approaches only when the CS is high (Supplementary Figure 4), supplemented by coclustering of multiple signatures for the same phenomena (<xref rid="fig0002" ref-type="fig">Fig. 2</xref> and <xref rid="fig0003" ref-type="fig">Fig. 3</xref>) confirm that our approach does not only yield statistically but also biologically significant results. Signature and data permutation approaches show that our approach is valid for signatures of a wide range of sizes, down to only few genes. In the RosettaSX analytical web platform, we link the signature translatability assessment with downstream tools that allow disentangling biological gene expression phenotypes in large-scale datasets.</p>
    <p id="para0043">Gene expression signatures are a key element to reduce complexity and add interpretability in analyses of expression phenotypes. RosettaSX provides access to signature scores and analysis options for more than 11,000 cancer samples of patients and tumor models in more than 30 different cancer indications. Relying on efficient and straightforward established methods that are distilled into our workflow, this resource can help users to robustly characterize signatures as biomarkers in widely used multiomics data sets.</p>
  </sec>
  <sec id="sec0009">
    <title>Author contributions</title>
    <p id="para0045"><bold>Julian Kreis</bold>: Writing - Original Draft, Writing - Review &amp; Editing, Conceptualization, Methodology, Software, Visualization, Data Curation, Formal Analysis <bold>Boro Nedic</bold>: Software, Visualization <bold>Johanna Mazur</bold>: Writing - Review &amp; Editing, Data Curation, <bold>Miriam Urban</bold>: Data Curation, Conceptualization, Methodology <bold>Sven-Eric-Schelhorn</bold>: Data Curation, <bold>Thomas Grombacher</bold>: Writing - Review &amp; Editing, Data Curation, <bold>Felix Geist</bold>: Writing - Review &amp; Editing, Data Curation, <bold>Benedikt Brors</bold>: Writing - Review &amp; Editing, <bold>Michael Zühlsdorf</bold>: Writing - Review &amp; Editing, <bold>Eike Staub</bold>: Writing - Review &amp; Editing, Supervision, Conceptualization, Methodology, Project administration</p>
  </sec>
  <sec id="sec0010">
    <title>Competing interests</title>
    <p id="para0046">All authors declare that they have no competing financial or nonfinancial interests that might have influenced the performance or presentation of the work described in this manuscript.</p>
  </sec>
</body>
<back>
  <ref-list id="cebibl1">
    <title>References</title>
    <ref id="bib0001">
      <label>1</label>
      <element-citation publication-type="journal" id="sbref0001">
        <person-group person-group-type="author">
          <name>
            <surname>Segal</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Friedman</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Koller</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Regev</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>A module map showing conditional activity of expression modules in cancer</article-title>
        <source>Nat. Genet.</source>
        <volume>36</volume>
        <year>2004</year>
        <fpage>1090</fpage>
        <lpage>1098</lpage>
        <pub-id pub-id-type="pmid">15448693</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0002">
      <label>2</label>
      <element-citation publication-type="journal" id="sbref0002">
        <person-group person-group-type="author">
          <name>
            <surname>Angelova</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Charoentong</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Hackl</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Fischer</surname>
            <given-names>M.L.</given-names>
          </name>
          <name>
            <surname>Snajder</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Krogsdam</surname>
            <given-names>A.M.</given-names>
          </name>
          <name>
            <surname>Waldner</surname>
            <given-names>M.J.</given-names>
          </name>
          <name>
            <surname>Bindea</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Mlecnik</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Galon</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy</article-title>
        <source>Genome Biol</source>
        <volume>16</volume>
        <year>2015</year>
        <fpage>1</fpage>
        <lpage>17</lpage>
        <pub-id pub-id-type="pmid">25583448</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0003">
      <label>3</label>
      <element-citation publication-type="journal" id="sbref0003">
        <person-group person-group-type="author">
          <name>
            <surname>Bild</surname>
            <given-names>A.H.</given-names>
          </name>
          <name>
            <surname>Potti</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Nevins</surname>
            <given-names>J.R.</given-names>
          </name>
        </person-group>
        <article-title>Linking oncogenic pathways with therapeutic opportunities</article-title>
        <source>Nat. Rev. Cancer</source>
        <volume>6</volume>
        <year>2006</year>
        <fpage>735</fpage>
        <lpage>741</lpage>
        <pub-id pub-id-type="pmid">16915294</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0004">
      <label>4</label>
      <element-citation publication-type="journal" id="sbref0004">
        <person-group person-group-type="author">
          <name>
            <surname>Taube</surname>
            <given-names>J.H.</given-names>
          </name>
          <name>
            <surname>Herschkowitz</surname>
            <given-names>J.I.</given-names>
          </name>
          <name>
            <surname>Komurov</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>A.Y.</given-names>
          </name>
          <name>
            <surname>Gupta</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Hartwell</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Onder</surname>
            <given-names>T.T.</given-names>
          </name>
          <name>
            <surname>Gupta</surname>
            <given-names>P.B.</given-names>
          </name>
          <name>
            <surname>Evans</surname>
            <given-names>K.W.</given-names>
          </name>
        </person-group>
        <article-title>Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes</article-title>
        <source>Proc. Natl. Acad. Sci. U. S. A.</source>
        <volume>107</volume>
        <year>2010</year>
        <fpage>15449</fpage>
        <lpage>15454</lpage>
        <pub-id pub-id-type="pmid">20713713</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0005">
      <label>5</label>
      <element-citation publication-type="journal" id="sbref0005">
        <person-group person-group-type="author">
          <name>
            <surname>Ragulan</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Eason</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Fontana</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Nyamundanda</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Tarazona</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Patil</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Poudel</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Lawlor</surname>
            <given-names>R.T.</given-names>
          </name>
          <name>
            <surname>Del Rio</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Koo</surname>
            <given-names>S.L.</given-names>
          </name>
        </person-group>
        <article-title>Analytical validation of multiplex biomarker assay to stratify colorectal cancer into molecular subtypes</article-title>
        <source>Sci. Rep.</source>
        <volume>9</volume>
        <year>2019</year>
        <fpage>1</fpage>
        <lpage>12</lpage>
        <pub-id pub-id-type="pmid">30626917</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0006">
      <label>6</label>
      <element-citation publication-type="journal" id="sbref0006">
        <person-group person-group-type="author">
          <name>
            <surname>Calza</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Hall</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Auer</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Bjöhle</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Klaar</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Kronenwett</surname>
            <given-names>U.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>E.T.</given-names>
          </name>
          <name>
            <surname>Miller</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Ploner</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Smeds</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients</article-title>
        <source>Breast Cancer Res</source>
        <volume>8</volume>
        <year>2006</year>
        <fpage>1</fpage>
        <lpage>9</lpage>
      </element-citation>
    </ref>
    <ref id="bib0007">
      <label>7</label>
      <element-citation publication-type="journal" id="sbref0007">
        <person-group person-group-type="author">
          <name>
            <surname>Farmer</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Bonnefoi</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Becette</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Tubiana-Hulin</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Fumoleau</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Larsimont</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>MacGrogan</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Bergh</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Cameron</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Goldstein</surname>
            <given-names>D.</given-names>
          </name>
        </person-group>
        <article-title>Identification of molecular apocrine breast tumours by microarray analysis</article-title>
        <source>Oncogene</source>
        <volume>24</volume>
        <year>2005</year>
        <fpage>4660</fpage>
        <lpage>4671</lpage>
        <pub-id pub-id-type="pmid">15897907</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0008">
      <label>8</label>
      <element-citation publication-type="journal" id="sbref0008">
        <person-group person-group-type="author">
          <name>
            <surname>Scott</surname>
            <given-names>D.W.</given-names>
          </name>
          <name>
            <surname>Gascoyne</surname>
            <given-names>R.D.</given-names>
          </name>
        </person-group>
        <article-title>The tumour microenvironment in B cell lymphomas</article-title>
        <source>Nat. Rev. Cancer</source>
        <volume>14</volume>
        <year>2014</year>
        <fpage>517</fpage>
        <lpage>534</lpage>
        <pub-id pub-id-type="pmid">25008267</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0009">
      <label>9</label>
      <element-citation publication-type="journal" id="sbref0009">
        <person-group person-group-type="author">
          <name>
            <surname>Hanahan</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Weinberg</surname>
            <given-names>R.A.</given-names>
          </name>
        </person-group>
        <article-title>Hallmarks of cancer: the next generation</article-title>
        <source>Cell</source>
        <volume>144</volume>
        <year>2011</year>
        <fpage>646</fpage>
        <lpage>674</lpage>
        <pub-id pub-id-type="pmid">21376230</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0010">
      <label>10</label>
      <element-citation publication-type="journal" id="sbref0010">
        <person-group person-group-type="author">
          <name>
            <surname>Gnant</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Filipits</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Greil</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Stoeger</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Rudas</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Bago-Horvath</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Mlineritsch</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Kwasny</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Knauer</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Singer</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <article-title>Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone</article-title>
        <source>Ann. Oncol.</source>
        <volume>25</volume>
        <year>2014</year>
        <fpage>339</fpage>
        <lpage>345</lpage>
        <pub-id pub-id-type="pmid">24347518</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0011">
      <label>11</label>
      <element-citation publication-type="journal" id="sbref0011">
        <person-group person-group-type="author">
          <name>
            <surname>Koboldt</surname>
            <given-names>D.C.</given-names>
          </name>
          <name>
            <surname>Fulton</surname>
            <given-names>R.S.</given-names>
          </name>
          <name>
            <surname>McLellan</surname>
            <given-names>M.D.</given-names>
          </name>
          <name>
            <surname>Schmidt</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Kalicki-Veizer</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>McMichael</surname>
            <given-names>J.F.</given-names>
          </name>
          <name>
            <surname>Fulton</surname>
            <given-names>L.L.</given-names>
          </name>
          <name>
            <surname>Dooling</surname>
            <given-names>D.J.</given-names>
          </name>
          <name>
            <surname>Ding</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Mardis</surname>
            <given-names>E.R.</given-names>
          </name>
        </person-group>
        <article-title>Comprehensive molecular portraits of human breast tumours</article-title>
        <source>Nature</source>
        <volume>490</volume>
        <year>2012</year>
        <fpage>61</fpage>
        <lpage>70</lpage>
        <pub-id pub-id-type="pmid">23000897</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0012">
      <label>12</label>
      <element-citation publication-type="journal" id="sbref0012">
        <person-group person-group-type="author">
          <name>
            <surname>Laiho</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Kokko</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Vanharanta</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Salovaara</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Sammalkorpi</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Järvinen</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Mecklin</surname>
            <given-names>J.P.</given-names>
          </name>
          <name>
            <surname>Karttunen</surname>
            <given-names>T.J.</given-names>
          </name>
          <name>
            <surname>Tuppurainen</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Davalos</surname>
            <given-names>V.</given-names>
          </name>
        </person-group>
        <article-title>Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis</article-title>
        <source>Oncogene</source>
        <volume>26</volume>
        <year>2007</year>
        <fpage>312</fpage>
        <lpage>320</lpage>
        <pub-id pub-id-type="pmid">16819509</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0013">
      <label>13</label>
      <element-citation publication-type="journal" id="sbref0013">
        <person-group person-group-type="author">
          <name>
            <surname>Tsuji</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Midorikawa</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Takahashi</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Yagi</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Takayama</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Yoshida</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Sugiyama</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Aburatani</surname>
            <given-names>H.</given-names>
          </name>
        </person-group>
        <article-title>Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis</article-title>
        <source>Br. J. Cancer</source>
        <volume>106</volume>
        <year>2012</year>
        <fpage>126</fpage>
        <lpage>132</lpage>
        <pub-id pub-id-type="pmid">22095227</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0014">
      <label>14</label>
      <element-citation publication-type="journal" id="sbref0014">
        <person-group person-group-type="author">
          <name>
            <surname>Lamb</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Crawford</surname>
            <given-names>E.D.</given-names>
          </name>
          <name>
            <surname>Peck</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Modell</surname>
            <given-names>J.W.</given-names>
          </name>
          <name>
            <surname>Blat</surname>
            <given-names>I.C.</given-names>
          </name>
          <name>
            <surname>Wrobel</surname>
            <given-names>M.J.</given-names>
          </name>
          <name>
            <surname>Lerner</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Brunet</surname>
            <given-names>J.P.</given-names>
          </name>
          <name>
            <surname>Subramanian</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Ross</surname>
            <given-names>K.N.</given-names>
          </name>
        </person-group>
        <article-title>The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease</article-title>
        <source>Science</source>
        <volume>313</volume>
        <year>2006</year>
        <fpage>1929</fpage>
        <lpage>1935</lpage>
        <pub-id pub-id-type="pmid">17008526</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0015">
      <label>15</label>
      <element-citation publication-type="journal" id="sbref0015">
        <person-group person-group-type="author">
          <name>
            <surname>Goh</surname>
            <given-names>W.W.</given-names>
          </name>
          <name>
            <surname>Bin and Wong</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>Why breast cancer signatures are no better than random signatures explained</article-title>
        <source>Drug Discov. Today</source>
        <volume>23</volume>
        <year>2018</year>
        <fpage>1818</fpage>
        <lpage>1823</lpage>
        <pub-id pub-id-type="pmid">29864526</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0016">
      <label>16</label>
      <element-citation publication-type="journal" id="sbref0016">
        <person-group person-group-type="author">
          <name>
            <surname>Venet</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Dumont</surname>
            <given-names>J.E.</given-names>
          </name>
          <name>
            <surname>Detours</surname>
            <given-names>V.</given-names>
          </name>
        </person-group>
        <article-title>Most random gene expression signatures are significantly associated with breast cancer outcome</article-title>
        <source>PLoS Comput. Biol.</source>
        <volume>7</volume>
        <year>2011</year>
        <fpage>7</fpage>
      </element-citation>
    </ref>
    <ref id="bib0018">
      <label>17</label>
      <element-citation publication-type="journal" id="sbref0018">
        <person-group person-group-type="author">
          <name>
            <surname>Dhawan</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Barberis</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>W.C.</given-names>
          </name>
          <name>
            <surname>Domingo</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>West</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Maughan</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Scott</surname>
            <given-names>J.G.</given-names>
          </name>
          <name>
            <surname>Harris</surname>
            <given-names>A.L.</given-names>
          </name>
          <name>
            <surname>Buffa</surname>
            <given-names>F.M.</given-names>
          </name>
        </person-group>
        <article-title>Guidelines for using sigQC for systematic evaluation of gene signatures</article-title>
        <source>Nat. Protoc.</source>
        <volume>14</volume>
        <year>2019</year>
        <fpage>1377</fpage>
        <lpage>1400</lpage>
        <pub-id pub-id-type="pmid">30971781</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0019">
      <label>18</label>
      <element-citation publication-type="journal" id="sbref0019">
        <person-group person-group-type="author">
          <name>
            <surname>Berglund</surname>
            <given-names>A.E.</given-names>
          </name>
          <name>
            <surname>Welsh</surname>
            <given-names>E.A.</given-names>
          </name>
          <name>
            <surname>Eschrich</surname>
            <given-names>S.A.</given-names>
          </name>
        </person-group>
        <article-title>Characteristics and validation techniques for PCA-based gene-expression signatures</article-title>
        <source>Int. J. Genomics</source>
        <volume>2017</volume>
        <year>2017</year>
        <fpage>1</fpage>
        <lpage>13</lpage>
        <comment>2354564 <bold>2017</bold></comment>
      </element-citation>
    </ref>
    <ref id="bib0020">
      <label>19</label>
      <element-citation publication-type="journal" id="sbref0020">
        <person-group person-group-type="author">
          <name>
            <surname>Rahnenführer</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Domingues</surname>
            <given-names>F.S.</given-names>
          </name>
          <name>
            <surname>Maydt</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Lengauer</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>Calculating the statistical significance of changes in pathway activity from gene expression data</article-title>
        <source>Stat. Appl. Genet. Mol. Biol.</source>
        <volume>3</volume>
        <year>2004</year>
        <fpage>1</fpage>
        <lpage>31</lpage>
        <comment>16</comment>
      </element-citation>
    </ref>
    <ref id="bib0021">
      <label>20</label>
      <element-citation publication-type="journal" id="sbref0021">
        <person-group person-group-type="author">
          <name>
            <surname>Fan</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Salathia</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Kaeser</surname>
            <given-names>G.E.</given-names>
          </name>
          <name>
            <surname>Yung</surname>
            <given-names>Y.C.</given-names>
          </name>
          <name>
            <surname>Herman</surname>
            <given-names>J.L.</given-names>
          </name>
          <name>
            <surname>Kaper</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Fan</surname>
            <given-names>J.B.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Chun</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Characterizing transcriptional heterogeneity through pathway and gene set overdispersion analysis</article-title>
        <source>Nat. Methods</source>
        <volume>13</volume>
        <year>2016</year>
        <fpage>241</fpage>
        <lpage>244</lpage>
        <pub-id pub-id-type="pmid">26780092</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0022">
      <label>21</label>
      <element-citation publication-type="journal" id="sbref0022">
        <person-group person-group-type="author">
          <name>
            <surname>Staub</surname>
            <given-names>E.</given-names>
          </name>
        </person-group>
        <article-title>An interferon response gene expression signature is activated in a subset of medulloblastomas</article-title>
        <source>Transl. Oncol.</source>
        <volume>5</volume>
        <year>2012</year>
        <fpage>297</fpage>
        <lpage>304</lpage>
        <pub-id pub-id-type="pmid">22937182</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0023">
      <label>22</label>
      <element-citation publication-type="journal" id="sbref0023">
        <person-group person-group-type="author">
          <name>
            <surname>Robinson</surname>
            <given-names>M.D.</given-names>
          </name>
          <name>
            <surname>McCarthy</surname>
            <given-names>D.J.</given-names>
          </name>
          <name>
            <surname>Smyth</surname>
            <given-names>G.K.</given-names>
          </name>
        </person-group>
        <article-title>edgeR: a bioconductor package for differential expression analysis of digital gene expression data</article-title>
        <source>Bioinformatics</source>
        <volume>26</volume>
        <year>2009</year>
        <fpage>139</fpage>
        <lpage>140</lpage>
        <pub-id pub-id-type="pmid">19910308</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0024">
      <label>23</label>
      <element-citation publication-type="journal" id="sbref0024">
        <person-group person-group-type="author">
          <name>
            <surname>Ebi</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Tomida</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Takeuchi</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Arima</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Sato</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Mitsudomi</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Yatabe</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Osada</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Takahashi</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses</article-title>
        <source>Cancer Res</source>
        <volume>69</volume>
        <year>2009</year>
        <fpage>4027</fpage>
        <lpage>4035</lpage>
        <pub-id pub-id-type="pmid">19383916</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0025">
      <label>24</label>
      <mixed-citation publication-type="other" id="tboref0001">N. Harbeck, F. Penault-Llorca, J. Cortes, M. Gnant, N. Houssami, P. Poortmans, K. Ruddy, J. Tsang, F. Cardoso, Breast cancer, <italic>Nat. Rev. Dis. Primers</italic>, <bold>5</bold>, (1), 2019, 66</mixed-citation>
    </ref>
    <ref id="bib0026">
      <label>25</label>
      <element-citation publication-type="journal" id="sbref0026">
        <person-group person-group-type="author">
          <name>
            <surname>Hashmi</surname>
            <given-names>A.A.</given-names>
          </name>
          <name>
            <surname>Hashmi</surname>
            <given-names>K.A.</given-names>
          </name>
          <name>
            <surname>Irfan</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Khan</surname>
            <given-names>S.M.</given-names>
          </name>
          <name>
            <surname>Edhi</surname>
            <given-names>M.M.</given-names>
          </name>
          <name>
            <surname>Ali</surname>
            <given-names>J.P.</given-names>
          </name>
          <name>
            <surname>Hashmi</surname>
            <given-names>S.K.</given-names>
          </name>
          <name>
            <surname>Asif</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Faridi</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Khan</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters</article-title>
        <source>BMC Res. Notes</source>
        <volume>12</volume>
        <year>2019</year>
        <object-id pub-id-type="publisher-id">605</object-id>
      </element-citation>
    </ref>
    <ref id="bib0027">
      <label>26</label>
      <element-citation publication-type="journal" id="sbref0027">
        <person-group person-group-type="author">
          <name>
            <surname>Perou</surname>
            <given-names>C.M.</given-names>
          </name>
          <name>
            <surname>Sørile</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Eisen</surname>
            <given-names>M.B.</given-names>
          </name>
          <name>
            <surname>Van De Rijn</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Jeffrey</surname>
            <given-names>S.S.</given-names>
          </name>
          <name>
            <surname>Ress</surname>
            <given-names>C.A.</given-names>
          </name>
          <name>
            <surname>Pollack</surname>
            <given-names>J.R.</given-names>
          </name>
          <name>
            <surname>Ross</surname>
            <given-names>D.T.</given-names>
          </name>
          <name>
            <surname>Johnsen</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Akslen</surname>
            <given-names>L.A.</given-names>
          </name>
        </person-group>
        <article-title>Molecular portraits of human breast tumours</article-title>
        <source>Nature</source>
        <volume>406</volume>
        <year>2000</year>
        <fpage>747</fpage>
        <lpage>752</lpage>
        <pub-id pub-id-type="pmid">10963602</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0028">
      <label>27</label>
      <element-citation publication-type="journal" id="sbref0028">
        <person-group person-group-type="author">
          <name>
            <surname>Caicedo</surname>
            <given-names>H.H.</given-names>
          </name>
          <name>
            <surname>Hashimoto</surname>
            <given-names>D.A.</given-names>
          </name>
          <name>
            <surname>Caicedo</surname>
            <given-names>J.C.</given-names>
          </name>
          <name>
            <surname>Pentland</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Pisano</surname>
            <given-names>G.P.</given-names>
          </name>
        </person-group>
        <article-title>Overcoming barriers to early disease intervention</article-title>
        <source>Nat. Biotechnol.</source>
        <volume>38</volume>
        <year>2020</year>
        <fpage>669</fpage>
        <lpage>673</lpage>
        <pub-id pub-id-type="pmid">32444852</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0029">
      <label>28</label>
      <element-citation publication-type="journal" id="sbref0029">
        <person-group person-group-type="author">
          <name>
            <surname>Fougner</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Bergholtz</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Norum</surname>
            <given-names>J.H.</given-names>
          </name>
          <name>
            <surname>Sørlie</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>Re-definition of claudin-low as a breast cancer phenotype</article-title>
        <source>Nat. Commun.</source>
        <volume>11</volume>
        <year>2020</year>
        <fpage>1</fpage>
        <lpage>11</lpage>
        <pub-id pub-id-type="pmid">31911652</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0030">
      <label>29</label>
      <element-citation publication-type="journal" id="sbref0030">
        <person-group person-group-type="author">
          <name>
            <surname>Ades</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Zardavas</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Bozovic-Spasojevic</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Pugliano</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Fumagalli</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>De Azambuja</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Viale</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Sotiriou</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Piccart</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>Luminal B breast cancer: Molecular characterization, clinical management, and future perspectives</article-title>
        <source>J. Clin. Oncol.</source>
        <volume>32</volume>
        <year>2014</year>
        <fpage>2794</fpage>
        <lpage>2803</lpage>
        <pub-id pub-id-type="pmid">25049332</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0031">
      <label>30</label>
      <element-citation publication-type="journal" id="sbref0031">
        <person-group person-group-type="author">
          <name>
            <surname>Feeley</surname>
            <given-names>L.P.</given-names>
          </name>
          <name>
            <surname>Mulligan</surname>
            <given-names>A.M.</given-names>
          </name>
          <name>
            <surname>Pinnaduwage</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Bull</surname>
            <given-names>S.B.</given-names>
          </name>
          <name>
            <surname>Andrulis</surname>
            <given-names>I.L.</given-names>
          </name>
        </person-group>
        <article-title>Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information</article-title>
        <source>Mod. Pathol.</source>
        <volume>27</volume>
        <year>2014</year>
        <fpage>554</fpage>
        <lpage>561</lpage>
        <pub-id pub-id-type="pmid">24051696</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0032">
      <label>31</label>
      <element-citation publication-type="journal" id="sbref0032">
        <person-group person-group-type="author">
          <name>
            <surname>Toft</surname>
            <given-names>D.J.</given-names>
          </name>
          <name>
            <surname>Cryns</surname>
            <given-names>V.L.</given-names>
          </name>
        </person-group>
        <article-title>Minireview: basal-like breast cancer: from molecular profiles to targeted therapies</article-title>
        <source>Mol. Endocrinol.</source>
        <volume>25</volume>
        <year>2011</year>
        <fpage>199</fpage>
        <lpage>211</lpage>
        <pub-id pub-id-type="pmid">20861225</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0033">
      <label>32</label>
      <element-citation publication-type="journal" id="sbref0033">
        <person-group person-group-type="author">
          <name>
            <surname>Williams</surname>
            <given-names>L.A.</given-names>
          </name>
          <name>
            <surname>Butler</surname>
            <given-names>E.N.</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Allott</surname>
            <given-names>E.H.</given-names>
          </name>
          <name>
            <surname>Cohen</surname>
            <given-names>S.M.</given-names>
          </name>
          <name>
            <surname>Fuller</surname>
            <given-names>A.M.</given-names>
          </name>
          <name>
            <surname>Hoadley</surname>
            <given-names>K.A.</given-names>
          </name>
          <name>
            <surname>Perou</surname>
            <given-names>C.M.</given-names>
          </name>
          <name>
            <surname>Geradts</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Olshan</surname>
            <given-names>A.F.</given-names>
          </name>
        </person-group>
        <article-title>TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases</article-title>
        <source>npj Breast Cancer</source>
        <volume>4</volume>
        <year>2018</year>
        <fpage>1</fpage>
        <lpage>6</lpage>
        <pub-id pub-id-type="pmid">29354686</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0034">
      <label>33</label>
      <element-citation publication-type="journal" id="sbref0034">
        <person-group person-group-type="author">
          <name>
            <surname>Miller</surname>
            <given-names>L.D.</given-names>
          </name>
          <name>
            <surname>Smeds</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>George</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Vega</surname>
            <given-names>V.B.</given-names>
          </name>
          <name>
            <surname>Vergara</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Ploner</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Pawitan</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Hall</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Klaar</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>E.T.</given-names>
          </name>
        </person-group>
        <article-title>An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival</article-title>
        <source>Proc. Natl. Acad. Sci. U.S.A.</source>
        <volume>102</volume>
        <year>2005</year>
        <fpage>13550</fpage>
        <lpage>13555</lpage>
        <pub-id pub-id-type="pmid">16141321</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0035">
      <label>34</label>
      <element-citation publication-type="journal" id="sbref0035">
        <person-group person-group-type="author">
          <name>
            <surname>Troester</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Herschkowitz</surname>
            <given-names>J.I.</given-names>
          </name>
          <name>
            <surname>Oh</surname>
            <given-names>D.S.</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Hoadley</surname>
            <given-names>K.A.</given-names>
          </name>
          <name>
            <surname>Barbier</surname>
            <given-names>C.S.</given-names>
          </name>
          <name>
            <surname>Perou</surname>
            <given-names>C.M.</given-names>
          </name>
        </person-group>
        <article-title>Gene expression patterns associated with p53 status in breast cancer</article-title>
        <source>BMC Cancer</source>
        <volume>6</volume>
        <year>2006</year>
        <fpage>1</fpage>
        <lpage>13</lpage>
        <pub-id pub-id-type="pmid">16390557</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0036">
      <label>35</label>
      <element-citation publication-type="journal" id="sbref0036">
        <person-group person-group-type="author">
          <name>
            <surname>Budinska</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Popovici</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Tejpar</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>D'Ario</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Lapique</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Sikora</surname>
            <given-names>K.O.</given-names>
          </name>
          <name>
            <surname>Di Narzo</surname>
            <given-names>A.F.</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Graeme Hodgson</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Weinrich</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer</article-title>
        <source>J. Pathol.</source>
        <volume>231</volume>
        <year>2013</year>
        <fpage>63</fpage>
        <lpage>76</lpage>
        <pub-id pub-id-type="pmid">23836465</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0037">
      <label>36</label>
      <element-citation publication-type="journal" id="sbref0037">
        <person-group person-group-type="author">
          <name>
            <surname>Liberzon</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Birger</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Thorvaldsdóttir</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Ghandi</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Mesirov</surname>
            <given-names>J.P.</given-names>
          </name>
          <name>
            <surname>Tamayo</surname>
            <given-names>P.</given-names>
          </name>
        </person-group>
        <article-title>The molecular signatures database hallmark gene set collection</article-title>
        <source>Cell Syst</source>
        <volume>1</volume>
        <year>2015</year>
        <fpage>417</fpage>
        <lpage>425</lpage>
        <pub-id pub-id-type="pmid">26771021</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0038">
      <label>37</label>
      <element-citation publication-type="journal" id="sbref0038">
        <person-group person-group-type="author">
          <name>
            <surname>Lehmann</surname>
            <given-names>B.D.</given-names>
          </name>
          <name>
            <surname>Bauer</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Sanders</surname>
            <given-names>M.E.</given-names>
          </name>
          <name>
            <surname>Chakravarthy</surname>
            <given-names>A.B.</given-names>
          </name>
          <name>
            <surname>Shyr</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Pietenpol</surname>
            <given-names>J.A.</given-names>
          </name>
        </person-group>
        <article-title>Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies</article-title>
        <source>J. Clin. Invest.</source>
        <volume>121</volume>
        <year>2011</year>
        <fpage>2750</fpage>
        <lpage>2767</lpage>
        <pub-id pub-id-type="pmid">21633166</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0039">
      <label>38</label>
      <element-citation publication-type="journal" id="sbref0039">
        <person-group person-group-type="author">
          <name>
            <surname>Bertucci</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Finetti</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Birnbaum</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Basal breast cancer: a complex and deadly molecular subtype</article-title>
        <source>Curr. Mol. Med.</source>
        <volume>12</volume>
        <year>2011</year>
        <fpage>96</fpage>
        <lpage>110</lpage>
      </element-citation>
    </ref>
    <ref id="bib0040">
      <label>39</label>
      <element-citation publication-type="journal" id="sbref0040">
        <person-group person-group-type="author">
          <name>
            <surname>Schmidt</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Hellwig</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Hammad</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Othman</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Lohr</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Boehm</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Gebhard</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Petry</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Lebrecht</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors</article-title>
        <source>Clin. Cancer Res.</source>
        <volume>18</volume>
        <year>2012</year>
        <fpage>2695</fpage>
        <lpage>2703</lpage>
        <pub-id pub-id-type="pmid">22351685</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0041">
      <label>40</label>
      <element-citation publication-type="journal" id="sbref0041">
        <person-group person-group-type="author">
          <name>
            <surname>Shen</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Feng</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>Identification of distinct immune subtypes in colorectal cancer based on the stromal compartment</article-title>
        <source>Front. Oncol.</source>
        <volume>9</volume>
        <year>2020</year>
        <fpage>1</fpage>
        <lpage>15</lpage>
      </element-citation>
    </ref>
    <ref id="bib0042">
      <label>41</label>
      <element-citation publication-type="journal" id="sbref0042">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Gu</surname>
            <given-names>L.N.</given-names>
          </name>
          <name>
            <surname>Shan</surname>
            <given-names>B.E.</given-names>
          </name>
          <name>
            <surname>Geng</surname>
            <given-names>C.Z.</given-names>
          </name>
          <name>
            <surname>Sang</surname>
            <given-names>M.X.</given-names>
          </name>
        </person-group>
        <article-title>Biomarkers for EMT and MET in breast cancer: an update (review)</article-title>
        <source>Oncol. Lett.</source>
        <volume>12</volume>
        <year>2016</year>
        <fpage>4869</fpage>
        <lpage>4876</lpage>
        <pub-id pub-id-type="pmid">28105194</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0043">
      <label>42</label>
      <element-citation publication-type="journal" id="sbref0043">
        <person-group person-group-type="author">
          <name>
            <surname>Savci-Heijink</surname>
            <given-names>C.D.</given-names>
          </name>
          <name>
            <surname>Halfwerk</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Hooijer</surname>
            <given-names>G.K.J.</given-names>
          </name>
          <name>
            <surname>Koster</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Horlings</surname>
            <given-names>H.M.</given-names>
          </name>
          <name>
            <surname>Meijer</surname>
            <given-names>S.L.</given-names>
          </name>
          <name>
            <surname>van de Vijver</surname>
            <given-names>M.J.</given-names>
          </name>
        </person-group>
        <article-title>Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior</article-title>
        <source>Breast Cancer Res. Treat.</source>
        <volume>174</volume>
        <year>2019</year>
        <fpage>649</fpage>
        <lpage>659</lpage>
        <pub-id pub-id-type="pmid">30610490</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0044">
      <label>43</label>
      <element-citation publication-type="journal" id="sbref0044">
        <person-group person-group-type="author">
          <name>
            <surname>Berdiel-Acer</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Maia</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Hristova</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Borgoni</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Vetter</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Burmester</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Becki</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Michels</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Abnaof</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Binenbaum</surname>
            <given-names>I.</given-names>
          </name>
        </person-group>
        <article-title>Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts</article-title>
        <source>Oncogene</source>
        <volume>40</volume>
        <year>2021</year>
        <fpage>2651</fpage>
        <lpage>2666</lpage>
        <pub-id pub-id-type="pmid">33692466</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0045">
      <label>44</label>
      <element-citation publication-type="journal" id="sbref0045">
        <person-group person-group-type="author">
          <name>
            <surname>Sukswai</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Lyapichev</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Khoury</surname>
            <given-names>J.D.</given-names>
          </name>
          <name>
            <surname>Medeiros</surname>
            <given-names>L.J.</given-names>
          </name>
        </person-group>
        <article-title>Diffuse large B-cell lymphoma variants: an update</article-title>
        <source>Pathology</source>
        <volume>52</volume>
        <year>2020</year>
        <fpage>53</fpage>
        <lpage>67</lpage>
        <pub-id pub-id-type="pmid">31735345</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0046">
      <label>45</label>
      <element-citation publication-type="journal" id="sbref0046">
        <person-group person-group-type="author">
          <name>
            <surname>Basso</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Dalla-Favera</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>Germinal centres and B cell lymphomagenesis</article-title>
        <source>Nat. Rev. Immunol.</source>
        <volume>15</volume>
        <year>2015</year>
        <fpage>172</fpage>
        <lpage>184</lpage>
        <pub-id pub-id-type="pmid">25712152</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0047">
      <label>46</label>
      <element-citation publication-type="journal" id="sbref0047">
        <person-group person-group-type="author">
          <name>
            <surname>Barretina</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Caponigro</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Stransky</surname>
            <given-names>N.</given-names>
          </name>
        </person-group>
        <article-title>The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity</article-title>
        <source>Nature</source>
        <volume>483</volume>
        <year>2012</year>
        <fpage>603</fpage>
        <lpage>607</lpage>
        <pub-id pub-id-type="pmid">22460905</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0048">
      <label>47</label>
      <element-citation publication-type="journal" id="sbref0048">
        <person-group person-group-type="author">
          <name>
            <surname>Meyers</surname>
            <given-names>R.M.</given-names>
          </name>
          <name>
            <surname>Bryan</surname>
            <given-names>J.G.</given-names>
          </name>
          <name>
            <surname>McFarland</surname>
            <given-names>J.M.</given-names>
          </name>
          <name>
            <surname>Weir</surname>
            <given-names>B.A.</given-names>
          </name>
          <name>
            <surname>Sizemore</surname>
            <given-names>A.E.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Dharia</surname>
            <given-names>N.V.</given-names>
          </name>
          <name>
            <surname>Montgomery</surname>
            <given-names>P.G.</given-names>
          </name>
          <name>
            <surname>Cowley</surname>
            <given-names>G.S.</given-names>
          </name>
          <name>
            <surname>Pantel</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells</article-title>
        <source>Nat. Genet.</source>
        <volume>49</volume>
        <year>2017</year>
        <fpage>1779</fpage>
        <lpage>1784</lpage>
        <pub-id pub-id-type="pmid">29083409</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0049">
      <label>48</label>
      <element-citation publication-type="journal" id="sbref0049">
        <person-group person-group-type="author">
          <name>
            <surname>Dempster</surname>
            <given-names>J.M.</given-names>
          </name>
          <name>
            <surname>Rossen</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Kazachkova</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Pan</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Kugener</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Root</surname>
            <given-names>D.E.</given-names>
          </name>
          <name>
            <surname>Tsherniak</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>Extracting biological insights from the project Achilles Genome-Scale CRISPR screens in cancer cell lines</article-title>
        <source>bioRxiv</source>
        <year>2019</year>
        <pub-id pub-id-type="doi">10.1101/720243</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0050">
      <label>49</label>
      <element-citation publication-type="journal" id="sbref0050">
        <person-group person-group-type="author">
          <name>
            <surname>Ghandi</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>F.W.</given-names>
          </name>
          <name>
            <surname>Jané-Valbuena</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Kryukov</surname>
            <given-names>G.V.</given-names>
          </name>
          <name>
            <surname>Lo</surname>
            <given-names>C.C.</given-names>
          </name>
          <name>
            <surname>McDonald</surname>
            <given-names>E.R.</given-names>
          </name>
          <name>
            <surname>Barretina</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Gelfand</surname>
            <given-names>E.T.</given-names>
          </name>
          <name>
            <surname>Bielski</surname>
            <given-names>C.M.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>H.</given-names>
          </name>
        </person-group>
        <article-title>Next-generation characterization of the Cancer Cell Line Encyclopedia</article-title>
        <source>Nature</source>
        <volume>569</volume>
        <year>2019</year>
        <fpage>503</fpage>
        <lpage>508</lpage>
        <pub-id pub-id-type="pmid">31068700</pub-id>
      </element-citation>
    </ref>
    <ref id="bib0051">
      <label>50</label>
      <element-citation publication-type="journal" id="sbref0051">
        <person-group person-group-type="author">
          <name>
            <surname>Goldman</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Craft</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Hastie</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Repečka</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>McDade</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Kamath</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Banerjee</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Luo</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Rogers</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Brooks</surname>
            <given-names>A.N.</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Haussler</surname>
            <given-names>D.</given-names>
          </name>
        </person-group>
        <article-title>The UCSC Xena platform for cancer genomics data visualization and interpretation Paper Introduction</article-title>
        <source>bioRxiv</source>
        <year>2018</year>
        <pub-id pub-id-type="doi">10.1101/326470</pub-id>
      </element-citation>
    </ref>
    <ref id="bib52">
      <label>51</label>
      <element-citation publication-type="journal" id="optKOoJ37owuo">
        <person-group person-group-type="author">
          <name>
            <surname>Schmitz</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Wright</surname>
            <given-names>G.W.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>C.A.</given-names>
          </name>
          <name>
            <surname>Johnson</surname>
            <given-names>C.A.</given-names>
          </name>
          <name>
            <surname>Phelan</surname>
            <given-names>J.D.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J.Q.</given-names>
          </name>
          <name>
            <surname>Roulland</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kasbekar</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Young</surname>
            <given-names>R.M.</given-names>
          </name>
          <name>
            <surname>Shaffer</surname>
            <given-names>A.L.</given-names>
          </name>
          <name>
            <surname>Hodson</surname>
            <given-names>D.J.</given-names>
          </name>
          <name>
            <surname>Xiao</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>.X</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Du</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Chan</surname>
            <given-names>W.C.</given-names>
          </name>
          <name>
            <surname>Jaffe</surname>
            <given-names>E.S.</given-names>
          </name>
          <name>
            <surname>Gascoyne</surname>
            <given-names>R.D.</given-names>
          </name>
          <name>
            <surname>Connors</surname>
            <given-names>J.M.</given-names>
          </name>
          <name>
            <surname>Campo</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Lopez-Guillermo</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Rosenwald</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Ott</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Delabie</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Rimsza</surname>
            <given-names>L.M.</given-names>
          </name>
          <name>
            <surname>Tay Kuang Wei</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Zelenetz</surname>
            <given-names>A.D.</given-names>
          </name>
          <name>
            <surname>Leonard</surname>
            <given-names>J.P.</given-names>
          </name>
          <name>
            <surname>Bartlett</surname>
            <given-names>N.L.</given-names>
          </name>
          <name>
            <surname>Tran</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Shetty</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Soppet</surname>
            <given-names>D.R.</given-names>
          </name>
          <name>
            <surname>Pittaluga</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Wilson</surname>
            <given-names>W.H.</given-names>
          </name>
          <name>
            <surname>Staudt</surname>
            <given-names>L.M</given-names>
          </name>
        </person-group>
        <article-title>The Molecular Signatures Database Hallmark Gene Set Collection</article-title>
        <source>N Engl J Med</source>
        <volume>378</volume>
        <issue>15</issue>
        <year>2018</year>
        <fpage>1396</fpage>
        <lpage>1407</lpage>
        <pub-id pub-id-type="doi">10.1056/NEJMoa1801445</pub-id>
        <pub-id pub-id-type="pmid">29641966</pub-id>
      </element-citation>
    </ref>
  </ref-list>
  <sec id="sec0012" sec-type="supplementary-material">
    <label>Appendix</label>
    <title>Supplementary materials</title>
    <p id="para0047a">
      <supplementary-material content-type="local-data" id="ecom0001">
        <media xlink:href="mmc1.docx">
          <alt-text>Image, application 1</alt-text>
        </media>
      </supplementary-material>
    </p>
  </sec>
  <ack id="ack0001">
    <title>Funding</title>
    <p id="para0048">Funding for the PhD project of JK has been provided by Merck Healthcare KGaA, Darmstadt, Germany.</p>
  </ack>
  <fn-group>
    <fn id="sec0011" fn-type="supplementary-material">
      <p id="para0001a">Supplementary material associated with this article can be found, in the online version, at doi:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.neo.2021.08.005" id="interref0001">10.1016/j.neo.2021.08.005</ext-link>.</p>
    </fn>
  </fn-group>
</back>
